Company: CI
Filing Date: 2025-03-14
Form Type: DEF 14A
Source: 0001739940-25-000015
Chunk: 47

Company: Cigna Group
Filing Date: 2025-03-14
Form: DEF 14A
Chunk 47
---
 and Post-Termination Paymentssummarizes any employment agreements, our severance, and other post-termination arrangements, as well as our change of control arrangements.                                                      |     | Page74 |
| Compensation Policies and Governance Practicesdescribes our stock ownership guidelines, our clawback policy, our hedging and pledging restrictions, and risk oversight.                                                                                |     | Page77 |

| 52 |     | The Cigna Group| 2025 Notice of Annual Meeting of Shareholders and Proxy Statement |

| COMPENSATION MATTERS |

#### Executive Summary
2024 Performance and Business Highlights

The Cigna Group is a global health company committed to creating a better future built on the vitality of every individual and every community. We relentlessly challenge ourselves to partner and innovate solutions for better health. In 2024, The Cigna Group advanced our strategic goals, delivering value for the benefit of our customers, patients, clients, shareholders, and other stakeholders.

• We began dispensing a HUMIRA interchangeable biosimilar to eligible Accredo by Evernorth ® patients with $0 cost to our patients – and by year-end 2024 biosimilar use for eligible HUMIRA scripts reached nearly 50%. In addition, we announced a STELARA biosimilar for $0 cost to our patients, which will be available in early 2025.

• We enrolled approximately 8 million lives in EncircleRx, a new solution for managing GLP-1 medications for weight loss and diabetes. We are supporting the best possible patient health outcomes by providing those on a GLP-1 additional lifestyle support and tools to sustain long-term change.

• We delivered approximately $275 million in patient savings for insulin and other diabetes medications since launching the Patient Assurance Program in 2019.

• We expanded patient protection against the high cost of gene therapies for 7.5 million people.

• We launched Evernorth Behavioral Care Group to provide evidence-based, outcome-driven care both online and in person through a simpler care delivery experience. Patients can book an appointment and are guaranteed to see a clinician who matches their unique goals and preferences within 72 hours, contributing to 84% of patients experiencing significant reductions in depression and anxiety symptoms as of August 2024.

• We also addressed industry challenges around long wait times for care by expanding MD Live by Evernorth ® urgent care services with the launch of an “E-Treatment” option. Now, approximately 12.5 million Cigna Healthcare customers have quick, flexible access to urgent care from